Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00687297. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
It has been shown in previous studies that the ability to treat lung cancer could be significantly improved by not only targeting the tumor cells directly with chemotherapy, but also by cutting off the blood supply to the cancer cells. Blood vessels that supply the tumor are formed through a process called angiogenesis. Vandetanib is an investigational drug that acts by producing what is called an anti-angiogenic effect. An Anti-angiogenic effect is able to inhibit the development of new blood vessels required by tumors to survive by blocking the growth factors needed to form new blood vessels. The purpose of this study is to determine if the addition of vandetanib to a standard chemotherapy regimen will slow or stop the growth of the cancer for a longer period of time compared to the time period generally gained from the use of standard chemotherapy alone
Study identification
- NCT ID
- NCT00687297
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 162 participants
Conditions and interventions
Conditions
Interventions
- vandetanib induction Drug
- Docetaxel Drug
- Carboplatin Drug
- Placebo Drug
- Vandetanib maintenance Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2008 (Type not available)
- Primary completion
- Jan 2011 (Actual)
- Completion
- Apr 2011 (Actual)
- Last update posted
- May 30, 2018
2008 – 2011
United States locations
- U.S. sites
- 30
- U.S. states
- 16
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boca Raton Community Hospital | Boca Raton | Florida | 33486 | — |
| Lakeland Regional Cancer Center | Lakeland | Florida | 33805 | — |
| SwedishAmerican Hospital | Rockford | Illinois | 61104 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Ochsner Clinic | New Orleans | Louisiana | 70121 | — |
| Greater Baltimore Medical Center | Baltimore | Maryland | 21204 | — |
| St. Joseph Mercy Hospital- Ann Arbor | Ann Arbor | Michigan | 48106 | — |
| West Michigan Cancer Center | Kalamazoo | Michigan | 49007 | — |
| Metro-Minnesota CCOP | Saint Louis Park | Minnesota | 55416 | — |
| Ocean Medical Center | Brick | New Jersey | 08724 | — |
| Morristown Memorial Hospital | Morristown | New Jersey | 07960 | — |
| Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Riverview Medical Center | Red Bank | New Jersey | 07701 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Aultman Hospital | Canton | Ohio | 44710 | — |
| Abington Memorial Hospital | Abington | Pennsylvania | 19001 | — |
| Hematology & Oncology of NEPA | Dunmore | Pennsylvania | 18512 | — |
| Lancaster General Hospital | Lancaster | Pennsylvania | 17604 | — |
| Central PA Hematology & Medical Oncology Associaties | Lemoyne | Pennsylvania | 17043 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Albert Einstein Cancer Center | Philadelphia | Pennsylvania | 19141 | — |
| The Reading Hospital and Medical Center | Reading | Pennsylvania | 19610 | — |
| Mount Nittany Medical Center | State College | Pennsylvania | 16803 | — |
| Sanford Clinic | Sioux Falls | South Dakota | 57104 | — |
| Meharry Medical College | Nashville | Tennessee | 37208 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Charleston Area Medical Center | Charleston | West Virginia | 25304 | — |
| St. Vincent Hospital | Green Bay | Wisconsin | 45301 | — |
| Gundersen Lutheran | La Crosse | Wisconsin | 54601 | — |
| Regional Cancer Center | Waukesha | Wisconsin | 53188 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00687297, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 30, 2018 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00687297 live on ClinicalTrials.gov.